Anti-cancer and anti-inflammatory therapeutics and methods thereof
US11116851B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 18, 2016 |
| Grant date | Sep 14, 2021 |
| Priority date | — |
| Expiry date | Oct 20, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/86
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the discovery of a vital new component of the Wnt pathway that regulates trafficking of β-catenin to the cell nucleus and novel therapeutic approaches to cancer treatment. Disclosed herein is a previously unknown, essential component of the Wnt/β-catenin signaling pathway that governs the quantity of β-catenin delivered to the cell nucleus. This intracellular inhibitor of β-catenin signaling (IBS) is transcribed from a second transcriptional start site adjacent to exon 3 of the Dkk3 gene and is required for early mouse development. IBS captures β-catenin destined for the nucleus in a complex with β-TrCP that is bound to the actin cytoskeleton and unavailable for nuclear translocation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.